Inhibrx Biosciences, Inc. (INBX) vs Ultragenyx Pharmaceutical Inc. (RARE)

Inhibrx Biosciences, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Inhibrx Biosciences, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.5B and $1.5B). Inhibrx Biosciences, Inc. has the higher net margin (0.00% vs −81.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Inhibrx Biosciences, Inc. leads on 9 and Ultragenyx Pharmaceutical Inc. on 5.

Valuation

Metric INBX RARE Biotechnology median
P/E n/m n/m 7.88
P/S 495.33 2.06 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 508.96 1.65 10.73
Earnings yield (8.91%) (40.28%) (28.84%)
Free cash flow yield (8.45%) (33.43%) (23.03%)

Profitability

Metric INBX RARE Biotechnology median
Gross margin 100.00% 83.12% 65.16%
Operating margin 0.00% (73.64%) 0.00%
Net margin 0.00% (81.73%) 0.00%
Free cash flow margin 0.00% (68.90%) 0.00%
Return on equity (1,773.60%) 838.86% (57.72%)
Return on assets (75.44%) (45.60%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric INBX RARE Biotechnology median
Revenue growth (TTM) — 17.51% 5.64%
EPS growth (last fiscal year) (108.03%) 7.31% —
Revenue growth, 5-year CAGR — 19.95% 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric INBX RARE Biotechnology median
Debt to equity (3.33) 0.00 0.00
Current ratio 5.07 1.73 4.73
Net debt to EBITDA 0.18 1.35 0.96

Dividend

Metric INBX RARE Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric INBX RARE Biotechnology median
Market cap 1.48b 1.45b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack